Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that a number of novel therapies for the antihypertensive market are now unlikely to drive the value of the market because of disappointing Phase III clinical trial results. Generic erosion in all of the established antihypertensive drug classes will also be a factor in limiting the total market revenues in the next ten years, according to a new Pharmacor study entitled Hypertension.

"One of the highly anticipated antihypertensive drugs showing poor Phase III trial performance was Bristol-Myers Squibb's (BMS) Vanlev, a dual angiotensin-converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor. Trial data show that Vanlev caused a threefold increase in the potentially fatal side-effect angioedema relative to that seen with ACE inhibitors," said Ruth Brown, Ph.D., an analyst at Decision Resources. "Because of this, the FDA has not currently approved Vanlev; however, BMS is now seeking its approval for resistant hypertension."

Disease Background-Hypertension

Hypertension, or high blood pressure, is called the "silent killer" because of its frequently asymptomatic nature and its role in the development of cardiovascular morbidities. Specifically, elevated blood pressure can cause hypertrophy of or ischemic damage to key organ systems, leading to a loss of function, or a predisposition to events such as myocardial infarction, stroke, congestive heart failure, and renal disease. The cardiovascular complications arising from severe hypertension have been recognized for more than 60 years. However, only in the past 30 years have physicians begun to treat patients with mildly elevated blood pressure to prevent complications.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Hypertension is a Cardium study.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.,

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Metabolic Disease Drug Market to Grow from $9 Billion in 2001 to $14 Billion in 2007, According to Decision Resources

View Now